

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/13226</b>  <b>(43) International Publication Date:</b> 8 July 1993 (08.07.93)
<b>(21) International Application Number:</b> PCT/US92/11348 <b>(22) International Filing Date:</b> 21 December 1992 (21.12.92)  <b>(30) Priority data:</b> 07/813,589 23 December 1991 (23.12.91) US  <b>(71) Applicant:</b> CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). <b>(72) Inventors:</b> KOLBERG, Janice, A. ; 131 Scotts Valley Road, Hercules, CA 94547 (US). URDEA, Michael, S. ; 100 Bunce Meadow Road, Alamo, CA 94507 (US). <b>(74) Agents:</b> PARK, Freddie, K. et al.; Morrison & Foerster, 755 Page Mill Road, Palo Alto, CA 94304 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> HAV PROBES FOR USE IN SOLUTION PHASE SANDWICH HYBRIDIZATION ASSAYS  <b>(57) Abstract</b>  Novel DNA probe sequences for detection of HAV in a sample in a solution phase sandwich hybridization assay are described. Amplified nucleic acid hybridization assays using the probes are exemplified.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

HAV PROBES FOR USE IN SOLUTION PHASE  
SANDWICH HYBRIDIZATION ASSAYS  
DESCRIPTION

Technical Field

10

This invention is in the field of nucleic acid hybridization assays. More specifically, it relates to novel nucleic acid probes for detecting Hepatitis A Virus (HAV).

15

Background Art

Hepatitis A virus is an RNA virus belonging to the picornavirus family and is thought to be responsible for at least 38% of all reported cases of hepatitis. Cohen et al. (J. Virol. 61:50-59, 1987) described the complete nucleotide sequence of wild-type Hepatitis A virus and compared the sequence with laboratory-adapted HAV strains and with other picornaviruses, finding most amino acid differences occurred in the capsid region, whereas most nucleotide differences occurred randomly throughout the genome.

25

Commonly owned U.S. 4,868,105 describes a solution phase nucleic acid sandwich hybridization assay in which analyte nucleic acid is first hybridized in solution to a labeling probe set and to a capturing probe set in a first vessel. The probe-analyte complex is then transferred to a second vessel that contains a solid-phase-immobilized probe that is complementary to a segment of the capturing probes. The segments hybridize to the immobilized probe, thus removing the complex from solution. Having the analyte in the form of an immobilized complex facilitates subsequent separation steps in the assay. Ultimately, single stranded segments

30

35

-2-

of the labeling probe set are hybridized to labeled probes, thus permitting the analyte-containing complex to be detected via a signal generated directly or indirectly from the label.

5                   Commonly owned European Patent Application (EPA) 883096976 discloses a variation in the assay described in U.S. 4,868,105 in which the signal generated by the labeled probes is amplified. The amplification involves the use of nucleic acid multimers. These  
10 multimers are branched polynucleotides that are constructed to have a segment that hybridizes specifically to the analyte nucleic acid or to a nucleic acid (branched or linear) that is bound to the analyte and iterations of a second segment that hybridize  
15 specifically to the labeled probe. In the assay employing the multimer, the initial steps of hybridizing the analyte to label or amplifier probe sets and capturing probe sets in a first vessel and transferring the complex to another vessel containing immobilized  
20 nucleic acid that will hybridize to a segment of the capturing probes are followed. The multimer is then hybridized to the immobilized complex and the labeled probes in turn hybridized to the second segment iterations on the multimer. Since the multimers provide  
25 a large number of sites for label probe attachment, the signal is amplified. Amplifier and capture probe sequences are disclosed for Hepatitis B virus, Neisseria gonorrhoeae, penicillin and tetracycline resistance in N. gonorrhoeae, and Chlamydia trachomatis.

30                   Commonly owned copending application Serial No. 558,897, filed 27 July 1990, describes the preparation of large comb-type branched polynucleotide multimers for use in the above-described solution phase assay. The combs provide greater signal enhancement in the assays than the  
35 smaller multimers.

-3-

Disclosure of the Invention

One aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a sandwich hybridization assay for HAV comprising a first segment having a nucleotide sequence substantially complementary to a segment of HAV nucleic acid, and a second segment having a nucleotide sequence substantially complementary to an oligonucleotide acid multimer.

Another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a sandwich hybridization assay for HAV comprising a first segment having a nucleotide sequence substantially complementary to a segment of HAV nucleic acid; and a second segment having a nucleotide sequence substantially complementary to an oligonucleotide bound to a solid phase.

Another aspect of the invention is a solution sandwich hybridization assay for detecting the presence of HAV in a sample, comprising

(a) contacting the sample under hybridizing conditions with an excess of (i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence substantially complementary to a segment of HAV nucleic acid and a second segment having a nucleotide sequence substantially complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence that is substantially complementary to a segment of HAV nucleic acid and a second segment that is substantially complementary to an oligonucleotide bound to a solid phase;

(b) contacting the product of step (a) under hybridizing conditions with said oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

-4-

- (d) contacting the product of step (c) under hybridization conditions with the nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to the second  
5 segment of the amplifier probe polynucleotide and a multiplicity of second oligonucleotide units that are substantially complementary to a labeled oligonucleotide;  
(e) removing unbound multimer;  
(f) contacting under hybridizing conditions the  
10 solid phase complex product of step (e) with the labeled oligonucleotide;  
(g) removing unbound labeled oligonucleotide;  
and  
(h) detecting the presence of label in the  
15 solid phase complex product of step (g).

Another aspect of the invention is a kit for the detection of HAV comprising a kit for the detection of HAV in a sample comprising in combination

- (i) a set of amplifier probe oligonucleotides  
20 wherein the amplifier probe oligonucleotide comprises a first segment having a nucleotide sequence substantially complementary to a segment of HAV nucleic acid and a second segment having a nucleotide sequence substantially complementary to an oligonucleotide unit of a nucleic  
25 acid multimer;

- (ii) a set of capture probe oligonucleotides wherein the capture probe oligonucleotide comprises a first segment having a nucleotide sequence that is substantially complementary to a segment of HAV nucleic  
30 acid and a second segment that is substantially complementary to an oligonucleotide bound to a solid phase;

- (iii) a nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is  
35 substantially complementary to the second segment of the amplifier probe polynucleotide and a multiplicity of

-5-

second oligonucleotide units that are substantially complementary to a labeled oligonucleotide; and  
(iv) a labeled oligonucleotide.

5 Modes for Carrying Out the Invention

Definitions

"Solution phase nucleic acid hybridization assay" intends the assay techniques described and claimed  
10 in commonly owned U.S. Patent No. 4,868,105 and EPA 883096976.

A "modified nucleotide" intends a nucleotide monomer that may be stably incorporated into a polynucleotide and which has an additional functional  
15 group. Preferably, the modified nucleotide is a 5'-cytidine in which the N<sup>4</sup>-position is modified to provide a functional hydroxy group.

An "amplifier multimer" intends a branched polynucleotide that is capable of hybridizing  
20 simultaneously directly or indirectly to analyte nucleic acid and to a multiplicity of polynucleotide iterations (i.e., either iterations of another multimer or iterations of a labeled probe). The branching in the multimers is effected through covalent bonds and the  
25 multimers are composed of two types of oligonucleotide units that are capable of hybridizing, respectively, to analyte nucleic acid or nucleic acid hybridized to analyte nucleic acid and to a multiplicity of labeled probes. The composition and preparation of such  
30 multimers are described in EPA 883096976 and U.S. Serial No. 558,897 filed 27 July 1990, the disclosures of which are incorporated herein by reference.

The term "amplifier probe" is intended as a branched or linear polynucleotide that is constructed to  
35 have a segment that hybridizes specifically to the analyte nucleic acid and iterations of a second segment that hybridize specifically to an amplifier multimer.



-6-

The term "capture probe" is intended as an oligonucleotide having a segment substantially complementary to a nucleotide sequence of the target DNA and a segment that is substantially complementary to a nucleotide sequence of a solid-phase-immobilized probe.

"Large" as used herein to describe the comb-type branched polynucleotides of the invention intends a molecule having at least about 15 branch sites and at least about 20 iterations of the labeled probe binding sequence.

"Comb-type" as used herein to describe the structure of the branched polynucleotides of the invention intends a polynucleotide having a linear backbone with a multiplicity of sidechains extending from the backbone.

A "cleavable linker molecule" intends a molecule that may be stably incorporated into a polynucleotide chain and which includes a covalent bond that may be broken or cleaved by chemical treatment or physical treatment such as by irradiation.

All nucleic acid sequences disclosed herein are written in a 5' to 3' direction. Nucleotides are designated according to the nucleotide symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. All nucleotide sequences disclosed are intended to include complementary sequences unless otherwise indicated.

#### Solution Phase Hybridization Assay

The general protocol for the solution phase sandwich hybridizations is as follows. The analyte nucleic acid is placed in a microtiter well with an excess of two single-stranded nucleic acid probe sets: (1) a set of capture probes, each having a first binding sequence substantially complementary to the analyte and a second binding sequence that is substantially complementary to nucleic acid bound to a solid support,



-7-

for example, the well surface or a bead, and (2) a set of amplifier probes (branched or linear), each having a first binding sequence that is capable of specific binding to the analyte and a second binding sequence that is capable of specific binding to a segment of the multimer. The resulting product is a three component nucleic acid complex of the two probes hybridized to the analyte by their first binding sequences. The second binding sequences of the probes remain as single-stranded segments as they are not substantially complementary to the analyte. This complex hybridizes to the immobilized probe on the solid surface via the second binding sequence of the capture probe. The resulting product comprises the complex bound to the solid surface via the duplex formed by the oligonucleotide bound to the solid surface and the second binding sequence of the capture probe. Unbound materials are then removed from the surface such as by washing.

The amplification multimer is then added to the bound complex under hybridization conditions to permit the multimer to hybridize to the available second binding sequence(s) of the amplifier probe of the complex. The resulting complex is then separated from any unbound multimer by washing. The labeled oligonucleotide is then added under conditions which permit it to hybridize to the complementary oligonucleotide units of the multimer. The resulting immobilized labeled nucleic acid complex is then washed to remove unbound labeled oligonucleotide, and read.

The analyte nucleic acids may be from a variety of sources, e.g., biological fluids or solids, and may be prepared for the hybridization analysis by a variety of means, e.g., proteinase K/SDS, chaotropic salts, etc. Also, it may be of advantage to decrease the average size of the analyte nucleic acids by enzymatic, physical or chemical means, e.g., restriction enzymes, sonication, chemical degradation (e.g., metal ions), etc. The frag-

-8-

ments may be as small as 0.1 kb, usually being at least about 0.5 kb and may be 1 kb or higher. The analyte sequence is provided in single-stranded form for analysis. Where the sequence is naturally present in single-stranded form, denaturation will not be required. However, where the sequence may be present in double-stranded form, the sequence should be denatured. Denaturation can be carried out by various techniques, such as alkali, generally from about 0.05 to 0.2 M hydroxide, formamide, salts, heat, enzymes, or combinations thereof.

The first binding sequences of the capture probe and amplifier probe that are substantially complementary to the analyte sequence will each be of at least 15 nucleotides, usually at least 25 nucleotides, and not more than about 5 kb, usually not more than about 1 kb, preferably not more than about 100 nucleotides. They will typically be approximately 30 nucleotides. They will normally be chosen to bind to different sequences of the analyte. The first binding sequences may be selected based on a variety of considerations. Depending upon the nature of the analyte, one may be interested in a consensus sequence, a sequence associated with polymorphisms, a particular phenotype or genotype, a particular strain, or the like.

The number of different amplifier and capture probes used influences the sensitivity of the assay, because the more probe sequences used, the greater the signal provided by the assay system. Furthermore, the use of more probe sequences allows the use of more stringent hybridization conditions, thereby reducing the incidence of false positive results. Thus, the number of probes in a set will be at least one capture probe and at least one amplifier probe, more preferably two capture and two amplifier probes, and most preferably 5-100 capture probes and 5-100 amplifier probes.

-9-

Oligonucleotide probes for HAV were designed by aligning the RNA sequences of five HAV isolates available from GenBank. Regions of greatest homology were chosen for capture probes, while regions of lesser homology were chosen as amplifier probes. Thus, as additional strains or isolates of HAV are made available, appropriate probes made be designed by aligning the sequence of the new strain or isolate with the nucleotide sequences used to design the probes of the present invention, and choosing regions of greatest homology for use as capture probes, with regions of lesser homology chosen as amplifier probes. The probe sequences of the presently preferred probe sets are contiguous and roughly correspond to nucleotides 1-1300 of the HAV genome. The nucleotide sequences of the presently preferred probe sets are shown in the examples.

The second binding sequences of the capture probe and amplifier probe are selected to be substantially complementary, respectively, to the oligonucleotide bound to the solid surface and to a segment of the multimer and so as to not be encountered by endogenous sequences in the sample/analyte. The second binding sequence may be contiguous to the first binding sequence or be spaced therefrom by an intermediate noncomplementary sequence. The probes may include other noncomplementary sequences if desired. These noncomplementary sequences must not hinder the binding of the binding sequences or cause nonspecific binding to occur.

The capture probe and amplifier probe may be prepared by oligonucleotide synthesis procedures or by cloning, preferably the former.

It will be appreciated that the binding sequences need not have perfect complementarity to provide homoduplexes. In many situations, heteroduplexes will suffice where fewer than about 10% of the bases are mismatches, ignoring loops of five or more nucleotides.

-10-

Accordingly, as used herein the term "complementary" intends exact complementarity wherein each base within the binding region corresponds exactly, and "substantially complementary" intends 90% or greater  
5 homology.

The labeled oligonucleotide will include a sequence substantially complementary to the repeated oligonucleotide units of the multimer. The labeled oligonucleotide will include one or more molecules  
10 ("labels"), which directly or indirectly provide a detectable signal. The labels may be bound to individual members of the substantially complementary sequence or may be present as a terminal member or terminal tail having a plurality of labels. Various means for  
15 providing labels bound to the oligonucleotide sequences have been reported in the literature. See, for example, Leary et al., Proc. Natl. Acad. Sci. USA (1983) 80:4045; Renz and Kurz, Nucl. Acids Res. (1984) 12:3435; Richardson and Gumpert, Nucl. Acids Res. (1983) 11:6167;  
20 Smith et al., Nucl. Acids Res. (1985) 13:2399; Meinkoth and Wahl, Anal. Biochem. (1984) 138:267. The labels may be bound either covalently or non-covalently to the substantially complementary sequence. Labels which may be employed include radionuclides, fluorescers,  
25 chemiluminescers, dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, enzyme subunits, metal ions, and the like. Illustrative specific labels include fluorescein, rhodamine, Texas red, phycoerythrin, umbelliferone, luminol, NADPH,  $\alpha$ - $\beta$ -galactosidase, horse-  
30 radish peroxidase, alkaline phosphatase, etc.

The ratio of capture probe and amplifier probe to anticipated moles of analyte will each be at least stoichiometric and preferably in excess. This ratio is preferably at least about 1.5:1, and more preferably at  
35 least 2:1. It will normally be in the range of 2:1 to  $10^6$ :1. Concentrations of each of the probes will generally range from about  $10^{-5}$  to  $10^{-9}$  M, with sample nucleic

-11-

acid concentrations varying from  $10^{-21}$  to  $10^{-12}$  M. The hybridization steps of the assay will generally take from about 10 minutes to 20 hours, frequently being completed in about 1 hour. Hybridization can be carried out at a mildly elevated temperature, generally in the range from about 20°C to 80°C, more usually from about 35°C to 70°C, particularly 65°C.

The hybridization reactions are usually done in an aqueous medium, particularly a buffered aqueous medium, which may include various additives. Additives which may be employed include low concentrations of detergent (0.01 to 1%), salts, e.g., sodium citrate (0.017 to 0.17 M), Ficoll, polyvinylpyrrolidone, carrier nucleic acids, carrier proteins, etc. Nonaqueous solvents may be added to the aqueous medium, such as dimethylformamide, dimethylsulfoxide, alcohols, and formamide. These other solvents are generally present in amounts ranging from 2 to 50%.

The stringency of the hybridization medium may be controlled by temperature, salt concentration, solvent system, and the like. Thus, depending upon the length and nature of the sequence of interest, the stringency will be varied.

Depending upon the nature of the label, various techniques can be employed for detecting the presence of the label. For fluorescers, a large number of different fluorometers are available. For chemiluminescers, luminometers or films are available. With enzymes, a fluorescent, chemiluminescent, or colored product can be provided and determined fluorometrically, luminometrically, spectrophotometrically or visually. The various labels which have been employed in immunoassays and the techniques applicable to immunoassays can be employed with the subject assays.

Kits for carrying out amplified nucleic acid hybridization assays according to the invention will comprise in packaged combination the following reagents:

-12-

the amplifier probe or set of probes; the capture probe or set of probes; the amplifier multimer; and an appropriate labeled oligonucleotide. These reagents will typically be in separate containers in the kit. The kit  
5 may also include a denaturation reagent for denaturing the analyte, hybridization buffers, wash solutions, enzyme substrates, negative and positive controls and written instructions for carrying out the assay.

The following examples further illustrate the  
10 invention. These examples are not intended to limit the invention in any manner.

### EXAMPLES

#### Example I


#### 15      Synthesis of Comb-type Branched Polynucleotide

This example illustrates the synthesis of a comb-type branched polynucleotide having 15 branch sites and sidechain extensions having three labeled probe binding sites. This polynucleotide was designed to be  
20 used in a solution phase hybridization as described in EPA 883096976.

All chemical syntheses of oligonucleotides were performed on an automatic DNA synthesizer (Applied Biosystems, Inc., (ABI) model 380 B). Phosphoramidite  
25 chemistry of the beta cyanoethyl type was used including 5'-phosphorylation which employed Phostel™ reagent (ABN). Standard ABI protocols were used except as indicated. Where it is indicated that a multiple of a cycle was used  
30 (e.g., 1.2 cycle), the multiple of the standard amount of amidite recommended by ABI was employed in the specified cycle. Appended hereto are the programs for carrying out cycles 1.2 and 6.4 as run on the Applied Biosystems Model 380 B DNA Synthesizer.

-13-

A comb body of the following structure was first prepared:



5




wherein X' is a branching monomer, and R is a periodate cleavable linker.

The portion of the comb body through the 15 (TTX') repeats is first synthesized using 33.8 mg aminopropyl-derivatized thymidine controlled pore glass (CPG) (2000 Å, 7.4 micromoles thymidine per gram support) with a 1.2 cycle protocol. The branching site nucleotide was of the formula:

15

20




25

30

where R<sup>2</sup> represents

35



-14-

For synthesis of the comb body (not including sidechains), the concentration of beta cyanoethylphosphoramidite monomers was 0.1 M for A, C, G and T, 0.15 M for the branching site monomer E, and 0.2 M for Phostel™ reagent. Detritylation was done with 3% trichloroacetic acid in methylene chloride using stepped flowthrough for the duration of the deprotection. At the conclusion the 5' DMT was replaced with an acetyl group.

Cleavable linker R and six base sidechain extensions of the formula 3'-RGTCAGTp (SEQ ID NO:1) were synthesized at each branching monomer site as follows. The base protecting group removal ( $R^2$  in the formula above) was performed manually while retaining the CPG support in the same column used for synthesizing the comb body. In the case of  $R^2$  = levulinyl, a solution of 0.5 M hydrazine hydrate in pyridine/glacial acetic acid (1:1 v/v) was introduced and kept in contact with the CPG support for 90 min with renewal of the liquid every 15 min, followed by extensive washing with pyridine/glacial acetic acid (1:1 v/v) and then by acetonitrile. After the deprotection the cleavable linker R and six base sidechain extensions were added using a 6.4 cycle.

In these syntheses the concentration of phosphoramidites was 0.1 M (except 0.2 M R and Phostel™ reagent; R was 2-(4-(4-(2-Dimethoxytrityloxy)ethyl)-phenoxy 2,3-di(benzoyloxy)-butyloxy)phenyl)ethyl-2-cyanoethyl-N,N-diisopropylphosphoramidite).

Detritylation is effected with a solution of 3% trichloroacetic acid in methylene chloride using continuous flowthrough, followed by a rinse solution of toluene/chloromethane (1:1 v/v). Branched polynucleotide chains were removed from the solid supports automatically in the 380B using the cycle "CE  $\text{NH}_3$ ." The ammonium hydroxide solution was collected in 4 ml screw-capped Wheaton vials and heated at 60°C for 12 hr to remove all base-protecting groups. After cooling



-15-

to room temperature the solvent was removed in a Speed-Vac evaporator and the residue dissolved in 100  $\mu$ l water.

3' backbone extensions (segment A), sidechain extensions and ligation template/linkers of the following structures were also made using the automatic synthesizer:

3' Backbone  
extension 3'-TCCGTATCCTGGGCACAGAGGTG Cp-5' (SEQ ID NO:2)

10 Sidechain  
extension 3'-GATGCG(TTCATGCTGTTGGTGTAG)<sub>3</sub>-5' (SEQ ID NO:3)

Ligation  
template for  
linking 3'  
backbone  
extension 3'-AAAAAAAAAAGCACCTp-5' (SEQ ID NO:4)

15 Ligation tem-  
plate for link-  
ing sidechain  
extension 3'-CGCATCACTGAC-5' (SEQ ID NO:5)

20

25

30

35

-16-

The crude comb body was purified by a standard polyacrylamide gel (7% with 7 M urea and 1X TBE running buffer) method.

The 3' backbone extension and the sidechain extensions were ligated to the comb body as follows. The comb body (4 pmole/ $\mu$ l), 3' backbone extension (6.25 pmole/ $\mu$ l), sidechain extension (93.75 pmole/ $\mu$ l), sidechain linking template (75 pmoles/ $\mu$ l) and backbone linking template (5 pmole/ $\mu$ l) were combined in 1 mM ATP/ 5 mM DTT/ 50 mM Tris-HCl, pH 8.0/ 10 mM MgCl<sub>2</sub>/ 2 mM spermidine, with 0.5 units/ $\mu$ l T4 polynucleotide kinase. The mixture was incubated at 37°C for 2 hr, then heated in a water bath to 95°C, and then slowly cooled to below 35°C over a 1 hr period. 2 mM ATP, 10 mM DTT, 14% polyethylene glycol, and 0.21 units/ $\mu$ l T4 ligase were added, and the mixture incubated for 16-24 hr at 23°C. The DNA was precipitated in NaCl/ethanol, resuspended in water, and subjected to a second ligation as follows. The mixture was adjusted to 1 mM ATP, 5 mM DTT, 14% polyethylene glycol, 50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 2 mM spermidine, 0.5 units/ $\mu$ l T4 polynucleotide kinase, and 0.21 units/ $\mu$ l T4 ligase were added, and the mixture incubated at 23°C for 16-24 hr. Ligation products were then purified by polyacrylamide gel electrophoresis.

After ligation and purification, a portion of the product was labeled with <sup>32</sup>P and subjected to cleavage at the site of R achieved by oxidation with aqueous NaIO<sub>4</sub> for 1 hr. The sample was then analyzed by PAGE to determine the number of sidechain extensions incorporated by quantitating the radioactive label in the bands on the gel. The product was found to have a total of 45 labeled probe binding sites.

-17-

Example IIProcedure for HAV Assay

A "15 X 3" amplified solution phase nucleic acid sandwich hybridization assay format was used in this assay. The "15 x 3" designation derives from the fact that the format employs two multimers: (1) an amplifier probe having a first segment (A) that binds to HAV and a second segment (B) that hybridizes to (2) an amplifier multimer having a first segment (B\*) that hybridizes to the segment (B) and fifteen iterations of a segment (C), wherein segment C hybridizes to three labeled oligonucleotides.

The amplifier and capture probe segments and their respective names used in this assay were as follows.

HAV Amplifier Probes

HAV.6 (SEQ ID NO:6)  
ATAGAAGTATTAGCCTAAGAGGTTTCACCCGTA  
HAV.7 (SEQ ID NO:7)  
CCGCCGCTGTTRCCCTATCCAARGCATCTCTTC  
HAV.8 (SEQ ID NO:8)  
TGAATGGTTTTTGTCTTAACAACTCACCAATAT  
HAV.9 (SEQ ID NO:9)  
GCATCCACTGGATGAGAGYCAGTCCTCCGGCGT  
HAV.10 (SEQ ID NO:10)  
CTARAGACAGCCCTGACARTCAATCCACTCAAT  
HAV.11 (SEQ ID NO:11)  
TTGCCCTAAGCACAGAGAGGTCTGRRATTAARC  
HAV.12 (SEQ ID NO:12)  
TCTCACAGRATCCCATTTAAGGCCAAATGRTGT  
HAV.13 (SEQ ID NO:13)  
AAGAACAGTCCAGCTGTCAATGGAGGGAYCCCC  
HAV.14 (SEQ ID NO:14)  
GTACCTCAGAGGCAAACACCACATAAGGCCCCA  
HAV.15 (SEQ ID NO:15)  
TTTAAGAATGAGGAAAAACCTAAATGCCCCTGA

-18-

HAV.16 (SEQ ID NO:16)  
GGAAAATWCCTTGTYTRGACATRTTCATTATTR  
HAV.17 (SEQ ID NO:17)  
ACAGGATGTGGTCAAGRCCACTCCCRACAGTCT  
5 HAV.18 (SEQ ID NO:18)  
GAATCATTGCTCTTCCTCAATRTCTGCCAAAG  
HAV.19 (SEQ ID NO:19)  
AAGCWCCAGTCACTGCAGTCCTAWCAACKGAYT  
HAV.20 (SEQ ID NO:20)  
10 GAACTGAAGATTGRTCCACAGAAGTRAARTAAG  
HAV.21 (SEQ ID NO:21)  
GTTCAAYYTGRTGTRAKCCAACCTCAGCWGTAT  
HAV.22 (SEQ ID NO:22)  
TWGAACYRGGTTTATCAACAGAGGTTYTCAARG  
15 HAV.23 (SEQ ID NO:23)  
GAATCARGAAAAAYTTYTCYCCCTGAGTYTCT  
HAV.24 (SEQ ID NO:24)  
ADAGAGCATGTGTAGTRAGCCAATCWGCAGAAT  
HAV.25 (SEQ ID NO:25)  
20 RTTTCACCACTCCAATTTTGCAACTTCATGRA  
HAV.26 (SEQ ID NO:26)  
AMCCTTGRACRGCAAACCTGCTCATTRTAYARTA  
HAV.27 (SEQ ID NO:27)  
TGCCAAATCTTGCATATGTRTGGTATCTCAACA  
25

HAV Capture Probes

HAV.1 (SEQ ID NO:28)  
CGCAACGGCCAGAGCCTAGGGCAAGGGGAGAGC  
HAV.2 (SEQ ID NO:29)  
30 CTCCATGCTAATCATGGAGTTGACCCCGCCGGG  
HAV.3 (SEQ ID NO:30)  
AMACATCTGYGTCCCAATTTAGACTCCTACAG  
HAV.4 (SEQ ID NO:31)  
GARAGCCAAGTTWACACTGCAAGGTGACGTYCC  
35 HAV.5 (SEQ ID NO:32)  
GCCTACCCCTTGTGGAAGATCAAAGAGRTTCAT  
HAV.28 (SEQ ID NO:33)

-19-

ARGGTGTRGGRTTATCTGAACTTGAATYTCAA

HAV.29 (SEQ ID NO:34)

GAACCATRGACARATYARYCCYCCYTGYTGRA

HAV.30 (SEQ ID NO:35)

5 AKGATGCTATHGAACCATARCTYTGGTCACYAG

HAV.31 (SEQ ID NO:36)

TGCAATTTAACARACCATGAGGATAAACAGTCA

HAV.32 (SEQ ID NO:37)

ATGGAACCTTTATTCTAACACATTGTTRATRT

10

Each amplifier probe contained, in addition to the sequences substantially complementary to the HAV sequences, the following 5' extension complementary to a segment of the amplifier multimer,

15 AGGCATAGGACCCGTGTCTT (SEQ ID NO:38).

Each capture probe contained, in addition to the sequences substantially complementary to HAV RNA, a downstream sequence complementary to DNA bound to the solid phase (XT1\*),

20 CTTCTTTGGAGAAAGTGGTG (SEQ ID NO:39).

Microtiter plates were prepared as follows.

White Microlite 1 Removawell strips (polystyrene microtiter plates, 96 wells/plate) were purchased from Dynatech Laboratories, Inc. Each well was filled with 200  $\mu$ l 1 N HCl and incubated at room temperature for 15-20 min. The plates were then washed 4 times with 1X PBS and the wells aspirated to remove liquid. The wells were then filled with 200  $\mu$ l 1 N NaOH and incubated at room temperature for 15-20 min. The plates were again washed 4 times with 1X PBS and the wells aspirated to remove liquid.

30

Poly(phe-lys) was purchased from Sigma Chemicals, Inc. This polypeptide has a 1:1 molar ratio of phe:lys and an average m.w. of 47,900 gm/mole. It has an average length of 309 amino acids and contains 155 amines/mole. A 1 mg/ml solution of the polypeptide was mixed with 2M NaCl/1X PBS to a final concentration of 0.1

35

-20-

mg/ml (pH 6.0). 100  $\mu$ L of this solution was added to each well. The plate was wrapped in plastic to prevent drying and incubated at 30°C overnight. The plate was then washed 4 times with 1X PBS and the wells aspirated  
5 to remove liquid.

The following procedure was used to couple the oligonucleotide XT1\* to the plates. Synthesis of XT1\* was described in EPA 883096976. 20 mg disuccinimidyl suberate was dissolved in 300  $\mu$ l dimethyl formamide  
10 (DMF). 26 OD<sub>260</sub> units of XT1\* was added to 100  $\mu$ l coupling buffer (50 mM sodium phosphate, pH 7.8). The coupling mixture was then added to the DSS-DMF solution and stirred with a magnetic stirrer for 30 min. An  
15 NAP-25 column was equilibrated with 10 mM sodium phosphate, pH 6.5. The coupling mixture DSS-DMF solution was added to 2 ml 10 mM sodium phosphate, pH 6.5, at 4°C. The mixture was vortexed to mix and loaded onto the  
20 equilibrated NAP-25 column. DSS-activated XT1\* DNA was eluted from the column with 3.5 ml 10 mM sodium phosphate, pH 6.5. 5.6 OD<sub>260</sub> units of eluted DSS-  
activated XT1\* DNA was added to 1500  $\mu$ l 50 mM sodium phosphate, pH 7.8. 50  $\mu$ l of this solution was added to each well and the plates were incubated overnight. The  
25 plate was then washed 4 times with 1X PBS and the wells aspirated to remove liquid.

Final stripping of plates was accomplished as follows. 200  $\mu$ L of 0.2N NaOH containing 0.5% (w/v) SDS was added to each well. The plate was wrapped in plastic and incubated at 65°C for 60 min. The plate was then  
30 washed 4 times with 1X PBS and the wells aspirated to remove liquid. The stripped plate was stored with desiccant beads at 2-8°C.

The HAV-infected cell culture (100% HAV infected FRhK4 cell line) and the uninfected cell culture  
35 (FRhK4 cell line) were prepared as follows.

Cells were trypsinized in STV (equal parts 0.25% trypsin and 1:2000 versene (Sigma Chemical Co.) in

-21-

PBS) and resuspended in 5 ml of the medium (DMEM with 20% FBS) the cells were grown in. The cells were then counted in a hemocytometer and diluted to  $10^5$  cells/ $10^4$   $\mu$ l,  $10^4$  cells/ $10^3$   $\mu$ l,  $10^3$  cells/ $10^2$   $\mu$ l, and  $10^2$  cells/ $10^1$   $\mu$ l.

5           A cocktail of the HAV-specific amplifier and capture probes was prepared in a proteinase K solution prepared by first adding 10 mg proteinase K to 5 ml capture diluent (53 mM Tris-HCl, pH 8.0/10.6 mM EDTA/1.3% SDS/16  $\mu$ g/ml sonicated salmon sperm DNA/5.3X SSC/1 mg/ml proteinase K/ 7% formamide). The cocktail  
10 contained 50 fmoles of each probe in 30  $\mu$ l buffer. 30  $\mu$ l of this solution was added to each well. 10  $\mu$ l of the appropriate dilution of the uninfected and infected cells as described above was then added to each well. Plates  
15 were covered and agitated to mix samples, then incubated at 65°C overnight.

The next morning the plates were cooled at room temperature for 10 minutes. The contents of each well were aspirated to remove all fluid, and the wells were  
20 washed 2X with washing buffer (0.1% SDS/0.015 M NaCl/ 0.0015 M sodium citrate). Amplifier multimer was then added to each well (20 fmoles/well in 4X SSC/ 0.1% SDS/ 0.5% Blocking Reagent (Boehringer Mannheim, catalog No. 1096 176)). After covering plates and agitating to mix  
25 the contents in the wells, the plates were incubated for 15 min at 65° C.

After a further 5-10 min period at room temperature, the wells were washed as described above.

Alkaline phosphatase label probe, disclosed in  
30 EP 883096976, was then added to each well (20 fmoles/well in 40  $\mu$ l 4X SSC/0.1% SDS/0.5% Blocking Reagent). After incubation at 55°C for 15 min, and 5-10 min at room temperature, the wells were washed twice as above and then 3x with 0.015 M NaCl/0.0015 M sodium citrate.

35           An enzyme-triggered dioxetane (Schaap et al., Tet. Lett. (1987) 28:1159-1162 and EPA Pub. No. 0254051) obtained from Lumigen, Inc., was employed. The detection

-22-

procedure was as follows. 30  $\mu$ l Lumiphos 530 (Lumigen) was added to each well. The wells were tapped lightly so that the reagent would fall to the bottom and gently swirled to distribute the reagent evenly over the bottom.

5 The wells were covered and incubated at 37°C for 40 min.

Plates were then read on a Dynatech ML 1000 luminometer (Dynatech Laboratories, Inc.). Output was given as the full integral of the light produced during the reaction.

10 Results are shown in the Table below. Results for each standard sample are expressed as the difference between the mean of the negative control plus two standard deviations and the mean of the sample minus two standard deviations (delta). If delta is greater than  
15 zero, the sample is considered positive. These results indicate a sensitivity of about  $10^3$ - $10^4$  HAV molecules.

Table

Sample	Amount	Delta
uninfected cells	$10^5$	--
uninfected cells	$10^4$	-0.26
uninfected cells	$10^3$	-0.25
uninfected cells	$10^2$	-0.16
25 HAV-infected cells	$10^5$	15.52
HAV-infected cells	$10^4$	2.59
HAV-infected cells	$10^3$	-0.09
HAV-infected cells	$10^2$	-0.03

30 Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in biochemistry, nucleic acid hybridization assays, and related fields are intended to be within the scope of the following claims.

35



-23-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Kolberg, Janice A.  
Urdea, Michael S.
- (ii) TITLE OF INVENTION: HAV PROBES FOR USE IN SOLUTION  
PHASE SANDWICH HYBRIDIZATION ASSAYS
- (iii) NUMBER OF SEQUENCES: 39
- 10 (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Morrison & Foerster  
(B) STREET: 545 Middlefield Road, Suite 200  
(C) CITY: Menlo Park  
(D) STATE: California  
(E) COUNTRY: USA  
(F) ZIP: 94025
- 15 (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:  
20 (A) APPLICATION NUMBER: UNKNOWN  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Fitts, Renee A.  
(B) REGISTRATION NUMBER: P35,136  
(C) REFERENCE/DOCKET NUMBER: 22300-20237.00
- 25 (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: 415-327-7250  
(B) TELEFAX: 415-327-2951  
(C) TELEX: 706141
- 30 (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

-24-

TGACTGN

7

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

10 CGTGTGGAGA CACGGGTCCT ATGCCT

26

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 60 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

20 GATGTGGTTG TCGTACTTGA TGTGGTTGTC GTACTTGATG TGGTTGTCGT ACTTGCGTAG

60

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCCACGAAAA AAAAAA

16

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

-25-

CAGTCACTAC GC

12

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

10 ATAGAAGTAT TAGCCTAAGA GGTTCACCC GTA 33

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

20 CCGCCGCTGT TRCCCTATCC AARGCATCTC TTC 33

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGAATGGTTT TTGTCTTAAC AACTCACCAA TAT 33

## (2) INFORMATION FOR SEQ ID NO:9:

30

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35

-26-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCATCCACTG GATGAGAGYC AGTCCTCCGG CGT

33

(2) INFORMATION FOR SEQ ID NO:10:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTARAGACAG CCCTGACART CAATCCACTC AAT

33

(2) INFORMATION FOR SEQ ID NO:11:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

20 TTGCCCTAAG CACAGAGAGG TCTGRRATTA ARC

33

(2) INFORMATION FOR SEQ ID NO:12:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

30 TCTCACAGRA TCCCATTTAA GGCCAAATGR TGT

33

(2) INFORMATION FOR SEQ ID NO:13:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-27-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAGAACAGTC CAGCTGTCAA TGGAGGGAYC CCC

33

## (2) INFORMATION FOR SEQ ID NO:14:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GTACCTCAGA GGCAAACACC ACATAAGGCC CCA

33

## (2) INFORMATION FOR SEQ ID NO:15:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

20 TTTAAGAATG AGGAAAAACC TAAATGCCCC TGA

33

## (2) INFORMATION FOR SEQ ID NO:16:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

30 GGAAAATWCC TTGTYTRGAC ATRTTCATTA TTR

33

## (2) INFORMATION FOR SEQ ID NO:17:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-28-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ACAGGATGTG GTCAAGRCCA CTCCTACAG TCT

33

(2) INFORMATION FOR SEQ ID NO:18:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GAATCATTG CTCTTCCTCA ATRCTGCCA AAG

33

(2) INFORMATION FOR SEQ ID NO:19:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

20 AAGCWCCAGT CACTGCAGTC CTAWCAACKG AYT

33

(2) INFORMATION FOR SEQ ID NO:20:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

30 GAACTGAAGA TTGRTCCACA GAAGTRAART AAG

33

(2) INFORMATION FOR SEQ ID NO:21:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-29-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GTTCAAYTG RTGTRAKCCA ACCTCAGCWG TAT

33

## (2) INFORMATION FOR SEQ ID NO:22:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TWGAACYRGG TTTATCAACA GAGGTTYTCA ARG

33

## (2) INFORMATION FOR SEQ ID NO:23:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

20 GAATCARGAA AAAYTTYTCY CCCTGAGTYY TCT

33

## (2) INFORMATION FOR SEQ ID NO:24:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

30 ADAGAGCATG TGTAGTRAGC CAATCWGCAG AAT

33

## (2) INFORMATION FOR SEQ ID NO:25:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-30-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

RTTTCACCAC RTCCAATTTT GCAACTTCAT GRA

33

(2) INFORMATION FOR SEQ ID NO:26:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AMCCTTGRAC RGCAAAGTGC TCATTRTAYA RTA

33

(2) INFORMATION FOR SEQ ID NO:27:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TGCCAAATCT TGCATATGTR TGGTATCTCA ACA

33

20 (2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CGCAACGGCC AGAGCCTAGG GCAAGGGGAG AGC

33

30 (2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35



-31-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CTCCATGCTA ATCATGGAGT TGACCCCGCC GGG

33

## (2) INFORMATION FOR SEQ ID NO:30:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AMACATCTGY GTCCCAATT TAGACTCCTA CAG

33

## (2) INFORMATION FOR SEQ ID NO:31:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GARAGCCAAG TTWACTGTC AAGGTGACGT YCC

33

## (2) INFORMATION FOR SEQ ID NO:32:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

30 GCCTACCCCT TGTGGAAGAT CAAAGAGRTT CAT

33

## (2) INFORMATION FOR SEQ ID NO:33:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-32-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

ARGGTGTRGG RTTTATCTGA ACTTGAATYT CAA

33

(2) INFORMATION FOR SEQ ID NO:34:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GAACCATRGC ACARATYARY CCYCCYTGYT GRA

33

(2) INFORMATION FOR SEQ ID NO:35:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AKGATGCTAT HGAACCATAR CTYTGGTCAC YAG

33

(2) INFORMATION FOR SEQ ID NO:36:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

TGCAATTTAA CARACCATGA GGATAACAG TCA

33

(2) INFORMATION FOR SEQ ID NO:37:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-33-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATGGAACCTT TATTCTAACY ACATTGTTRA TRT

33

(2) INFORMATION FOR SEQ ID NO:38:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

AGGCATAGGA CCCGTGTCTT

20

(2) INFORMATION FOR SEQ ID NO:39:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

20 CTTCTTTGGA GAAAGTGGTG

20

25

30

35

=

**Listings of All  
Cycles, Procedures, and Sequences  
Used to Synthesize the 15X Comb**

**Contained on the 3½" floppy disk  
for the 380B DNA Synthesizer**

FILE NAME	LAST ACCESS	DATE CREATED	FILE NAME	LAST ACCESS	DATE CREATED
FILE TYPE: SYNTHESIS CYCLE					
6.4XSC-5	08 27, 1991	08 27, 1991	6.4XS-5	08 27, 1991	08 27, 1991
1.2XD-6	08 27, 1991	08 27, 1991	1.2X-6	08 27, 1991	08 27, 1991
ssceaf3	01 07, 1990	01 07, 1990	ceaf3	01 07, 1990	01 07, 1990
10ceaf3	01 07, 1990	01 07, 1990	hpaf3	01 07, 1990	01 07, 1990
10hpaf3	01 07, 1990	01 07, 1990	rnaaf3	01 07, 1990	01 07, 1990
10rnaaf3	01 07, 1990	01 07, 1990	sscef3	01 07, 1990	01 07, 1990
cef3	01 07, 1990	01 07, 1990	10cef3	01 07, 1990	01 07, 1990
10hpaf3	01 07, 1990	01 07, 1990	rnaf3	01 07, 1990	01 07, 1990
10rnaaf3	01 07, 1990	01 07, 1990	ssceaf1	01 07, 1990	01 07, 1990
ceaf1	01 07, 1990	01 07, 1990	10ceaf1	01 07, 1990	01 07, 1990
hpaf1	01 07, 1990	01 07, 1990	10hpaf1	01 07, 1990	01 07, 1990
rnaaf1	01 07, 1990	01 07, 1990	10rnaaf1	01 07, 1990	01 07, 1990
sscef1	01 07, 1990	01 07, 1990	cef1	01 07, 1990	01 07, 1990
10cef1	01 07, 1990	01 07, 1990	10hpaf1	01 07, 1990	01 07, 1990
rnaf1	01 07, 1990	01 07, 1990	10rnaaf1	01 07, 1990	01 07, 1990

FILE TYPE: BOTTLE CHANGE PROCEDURE					
bc 18	07 01, 1986	07 01, 1986	bc 17	07 01, 1986	07 01, 1986
bc 16	07 01, 1986	07 01, 1986	bc 15	07 01, 1986	07 01, 1986
bc 14	07 01, 1986	07 01, 1986	bc 13	07 01, 1986	07 01, 1986
bc 12	07 01, 1986	07 01, 1986	bc 11	07 01, 1986	07 01, 1986
bc 10	07 01, 1986	07 01, 1986	bc 9	07 01, 1986	07 01, 1986
bc 8a	07 01, 1986	07 01, 1986	bc 7	07 01, 1986	07 01, 1986
bc 6	07 01, 1986	07 01, 1986	bc 5	07 01, 1986	07 01, 1986
bc 4	07 01, 1986	07 01, 1986	bc 3	07 01, 1986	07 01, 1986
bc 2	07 01, 1986	07 01, 1986	bc 1	07 01, 1986	07 01, 1986

FILE TYPE: END PROCEDURE					
CAP-PRIM	08 27, 1991	08 27, 1991	CE NH3	08 27, 1991	08 27, 1991
deprce	10 08, 1990	10 08, 1990	deprce10	10 08, 1990	10 08, 1990
deprhp	10 08, 1990	10 08, 1990	deprhp10	10 08, 1990	10 08, 1990
deprna	10 08, 1990	10 08, 1990	deprna10	10 08, 1990	10 08, 1990

FILE TYPE: BEGIN PROCEDURE					
STD PREP	08 27, 1991	08 27, 1991	phos003	07 01, 1986	07 01, 1986

FILE TYPE: SHUT-DOWN PROCEDURE					
clean003	07 01, 1986	07 01, 1986			

FILE TYPE: DNA SEQUENCES					
15X-2	08 27, 1991	08 27, 1991	15X-1	08 27, 1991	08 27, 1991

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	B	7	
1	10 #18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5	5 Advance FC	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6	28 Phos Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
7	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
8	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
14	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
15	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
16	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
18	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
19	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
20	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
22	4 Wait	15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
23	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
24	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
25	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
26	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
27	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
28	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
29	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
30	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
31	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
32	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
33	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
34	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
35	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
36	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
37	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
38	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
39	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
40	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
41	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
42	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
43	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
44	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
45	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
46	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
47	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
48	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
49	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
50	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
51	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
52	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
53	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
54	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
55	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
56	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
57	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
58	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
59	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
60	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
61	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
62	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
63	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
64	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
65	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
66	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
67	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
68	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
69	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
70	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
71	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
72	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
73	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
74	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
75	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
76	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
77	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
78	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
79	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
80	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
81	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
82	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
83	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
84	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
85	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
86	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
87	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
88	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
89	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
90	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
91	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
92	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
93	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
94	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
95	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
96	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
97	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
98	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
99	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
100	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
101	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
102	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
103	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
104	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
105	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
106	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
107	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
108	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
109	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
110	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
111	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
112	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
113	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
114	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
115	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
116	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
117	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
118	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
119	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
120	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
121	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
122	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
123	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
124	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
125	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
126	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
127	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
128	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
129	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
130	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
131	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
132	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
133	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)



[illegible]

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	5	6	7	
1	10 #18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5	5 Advance FC	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6	28 Phos Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
7	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
8	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
14	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
15	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
16	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
18	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
19	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
20	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
22	4 Wait	15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
23	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
24	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
25	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
26	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
27	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
28	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
29	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
30	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
31	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
32	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
33	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
34	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
35	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
36	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
37	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
38	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
39	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
40	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
41	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
42	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
43	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	5	6	7	
44	+47 Group 2 On	= 1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
45	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
46	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
47	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
48	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
49	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
50	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
51	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
52	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
53	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
54	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
55	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
56	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
57	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
58	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
59	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
60	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
61	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
62	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
63	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
64	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
65	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
66	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
67	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
68	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
69	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
70	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
71	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
72	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
73	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
74	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
75	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
76	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
77	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
78	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
79	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
80	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
81	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
82	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
83	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
84	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
85	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
86	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
87	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
88	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

STEP NUMBER	FUNCTION -# NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
89	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
90	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
91	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
92	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
93	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
94	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
95	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
96	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
97	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
98	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
99	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
100	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
101	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
102	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
103	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
104	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
105	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
106	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
107	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
108	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
109	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
110	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
111	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
112	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
113	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
114	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
115	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
116	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
117	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
118	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
119	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
120	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
121	19 B+TET To Col 1	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
122	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
123	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
124	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
125	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
126	20 B+TET To Col 2	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
127	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
128	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
129	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
130	90 TET To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
131	21 B+TET To Col 3	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
132	90 TET To Column	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
133	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

STEP NUMBER*	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
134	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
135	16 Cap Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
136	10 #18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
137	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
138	1 Block Flush	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
139	91 Cap To Column	22	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
140	10 #18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
141	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
142	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
143	1 Block Flush	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
144	81 #15 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
145	13 #15 To Column	22	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
146	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
147	4 Wait	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
148	2 Reverse Flush	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
149	1 Block Flush	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
150	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
151	34 Flush to Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
152	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
153	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
154	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
155	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
156	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
157	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
158	1 Block Flush	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
159	33 Cycle Entry	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
160	6 Waste-Port	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
161	37 Relay 3 Pulse	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
162	82 #14 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
163	30 #17 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
164	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
165	9 #18 To Column	20	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
166	11 #17 To Column	60	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
167	14 #14 To Column	20	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
168	2 Reverse Flush	7	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
169	11 #17 To Column	15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
170	34 Flush to Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
171	11 #17 To Column	15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
172	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
173	14 #14 To Column	20	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
174	34 Flush to Waste	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
175	7 Waste-Bottle	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
176	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
177	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
178	9 #18 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

[illegible]

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
1	10 \$18 To Waste	2	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2	9 \$18 To Column	9	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5	5 Advance FC	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6	28 Phos Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
7	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
8	90 TET To Column	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9	19 B+TET To Col 1	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11	19 B+TET To Col 1	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13	19 B+TET To Col 1	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
14	9 \$18 To Column	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
15	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
16	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17	10 \$18 To Waste	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
18	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
19	90 TET To Column	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
20	20 B+TET To Col 2	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
22	20 B+TET To Col 2	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
23	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
24	20 B+TET To Col 2	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
25	9 \$18 To Column	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
26	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
27	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
28	10 \$18 To Waste	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
29	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
30	90 TET To Column	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
31	21 B+TET To Col 3	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
32	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
33	21 B+TET To Col 3	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
34	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
35	21 B+TET To Col 3	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
36	9 \$18 To Column	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
37	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
38	4 Wait	20	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
39	2 Reverse Flush	5						Yes		Yes
40	10 \$18 To Waste	2						Yes		Yes
41	9 \$18 To Column	9						Yes		Yes
42	2 Reverse Flush	5						Yes		Yes
43	10 \$18 To Waste	3						Yes		Yes

(Continued next page.)

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
44	1 Block Flush	- 3						Yes		Yes
45	+45 Group 1 On	1						Yes		Yes
46	90 TET To Column	6						Yes		Yes
47	19 B+TET To Col 1	6						Yes		Yes
48	90 TET To Column	3						Yes		Yes
49	19 B+TET To Col 1	3						Yes		Yes
50	90 TET To Column	3						Yes		Yes
51	19 B+TET To Col 1	3						Yes		Yes
52	9 \$18 To Column	1						Yes		Yes
53	-46 Group 1 Off	1						Yes		Yes
54	+47 Group 2 On	1						Yes		Yes
55	10 \$18 To Waste	4						Yes		Yes
56	1 Block Flush	3						Yes		Yes
57	90 TET To Column	6						Yes		Yes
58	20 B+TET To Col 2	6						Yes		Yes
59	90 TET To Column	3						Yes		Yes
60	20 B+TET To Col 2	3						Yes		Yes
61	90 TET To Column	3						Yes		Yes
62	20 B+TET To Col 2	3						Yes		Yes
63	9 \$18 To Column	1						Yes		Yes
64	-48 Group 2 Off	1						Yes		Yes
5										
65	+49 Group 3 On	1						Yes		Yes
66	10 \$18 To Waste	4						Yes		Yes
67	1 Block Flush	3						Yes		Yes
68	90 TET To Column	6						Yes		Yes
69	21 B+TET To Col 3	6						Yes		Yes
70	90 TET To Column	3						Yes		Yes
71	21 B+TET To Col 3	3						Yes		Yes
72	90 TET To Column	3						Yes		Yes
73	21 B+TET To Col 3	3						Yes		Yes
74	9 \$18 To Column	1						Yes		Yes
75	-50 Group 3 Off	1						Yes		Yes
76	4 Wait	20						Yes		Yes
77	16 Cap Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
78	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
79	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
80	91 Cap To Column	12	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
81	10 \$18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
82	4 Wait	8	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
83	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
84	81 \$15 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
85	13 \$15 To Column	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
86	10 \$18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
87	4 Wait	15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
88	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)



[illegible]

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	S	6	7	
1	10 \$18 To Waste	2	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2	9 \$18 To Column	9	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5	5 Advance FC	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6	28 Phos Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
7	+45 Group 1 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
8	90 TET To Column	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9	19 B+TET To Col 1	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11	19 B+TET To Col 1	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13	19 B+TET To Col 1	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
14	9 \$18 To Column	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
15	-46 Group 1 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
16	+47 Group 2 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17	10 \$18 To Waste	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
18	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
19	90 TET To Column	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
20	20 B+TET To Col 2	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
22	20 B+TET To Col 2	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
23	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
24	20 B+TET To Col 2	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
25	9 \$18 To Column	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
26	-48 Group 2 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
27	+49 Group 3 On	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
28	10 \$18 To Waste	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
29	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
30	90 TET To Column	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
31	21 B+TET To Col 3	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
32	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
33	21 B+TET To Col 3	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
34	90 TET To Column	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
35	21 B+TET To Col 3	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
36	9 \$18 To Column	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
37	-50 Group 3 Off	1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
38	4 Wait	20	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
39	16 Cap Prep	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
40	2 Reverse Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
41	1 Block Flush	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
42	91 Cap To Column	12	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
43	10 \$18 To Waste	3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

(Continued next page.)

[illegible]

[illegible]

STEP NUMBER	FUNCTION # NAME	STEP TIME	STEP ACTIVE FOR BASES							SAFE STEP
			A	G	C	T	5	6	7	
1	2 Reverse Flush	60	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2	27 #10 To Collect	17	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4	1 Block Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5	4 Wait	660	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6	27 #10 To Collect	18	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
7	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
8	1 Block Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9	4 Wait	660	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10	27 #10 To Collect	18	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	1 Block Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13	4 Wait	660	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
14	27 #10 To Collect	17	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
15	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
16	1 Block Flush	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17	4 Wait	660	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
18	8 Flush To CLCT	9	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
19	27 #10 To Collect	14	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
20	8 Flush To CLCT	9	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	2 Reverse Flush	60	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
22	1 Block Flush	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
23	10 #18 To Waste	5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
24	9 #18 To Column	30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
25	2 Reverse Flush	60	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
26	1 Block Flush	10	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
27	42 #10 Vent	2	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

*deprotection  
Shutter count corrected to 131*



5'- GGT GTT TGG TTG TTG TTG TTG TTG TTG TTG TTG

TTG TTG TTG TTG TTG TTT TTT TTT TTT TTT TTT TT -3'

DNA SEQUENCE  
VERSION 2.00

SEQUENCE NAME: 15X-2  
SEQUENCE LENGTH: 10  
DATE: Aug 27, 199  
TIME: 14:06  
COMMENT:

5'- 77T GAC TGG T -3'

-54-

Claims

1. A synthetic oligonucleotide useful as an amplifier probe in a sandwich hybridization assay for HAV comprising

5 a first segment comprising a nucleotide sequence substantially complementary to a segment of HAV nucleic acid; and

a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide acid multimer,

10 wherein the HAV nucleic acid segment is selected from the group consisting of

ATAGAAGTATTAGCCTAAGAGGTTTCACCCGTA (SEQ ID NO:6),  
15 CCGCCGCTGTTRCCCTATCCAARGCATCTCTTC (SEQ ID NO:7),  
TGAATGGTTTTTGTCTTAACAACTCACCAATAT (SEQ ID NO:8),  
GCATCCACTGGATGAGAGYCAGTCCCTCCGGCGT (SEQ ID NO:9),  
CTARAGACAGCCCTGACARTCAATCCACTCAAT (SEQ ID NO:10),  
TTGCCCTAAGCACAGAGAGGTCTGRRATTAARC (SEQ ID NO:11),  
20 TCTCACAGRATCCCATTTAAGGCCAAATGRTGT (SEQ ID NO:12),  
AAGAACAGTCCAGCTGTCAATGGAGGGAYCCCC (SEQ ID NO:13),  
GTACCTCAGAGGCCAAACACCACATAAGGCCCCA (SEQ ID NO:14),  
TTTAAGAATGAGGAAAAACCTAAATGCCCTGA (SEQ ID NO:15),  
GGAAAATWCCTTGTYTRGACATRTTCATTATTR (SEQ ID NO:16),  
25 ACAGGATGTGGTCAAGRCCACTCCCRACAGTCT (SEQ ID NO:17),  
GAATCATTGCTCTTCCTCAATRTCTGCCAAAG (SEQ ID NO:18),  
AAGCWCCAGTCACTGCAGTCTTAWCAACKGAYT (SEQ ID NO:19),  
GAACTGAAGATTGRTCCACAGAAGTRAARTAAG (SEQ ID NO:20),  
GTTCAAYYTGRTGTRAKCCAACCTCAGCWGTAT (SEQ ID NO:21),  
30 TWGAACYRGTTTATCAACAGAGGTTYTCAARG (SEQ ID NO:22),  
GAATCARGAAAAAYTTYTCYCCCTGAGTYTCT (SEQ ID NO:23),  
ADAGAGCATGTGTAGTRAGCCAATCWGCAGAAT (SEQ ID NO:24),  
RTTTCACCACRTCCAATTTTGCAACTTCATGRA (SEQ ID NO:25),  
AMCCTTGACRGCAAACCTGCTCATTRTAYARTA (SEQ ID NO:26), and  
35 TGCCAAATCTTGCATATGTRTGGTATCTCAACA (SEQ ID NO:27).



-55-

2. The synthetic oligonucleotide of claim 1,  
wherein said second segment comprises

AGGCATAGGACCCGTGTCTT (SEQ ID NO:38).

5

3. A synthetic oligonucleotide useful as a  
capture probe in a sandwich hybridization assay for HAV  
comprising

a first segment comprising a nucleotide  
10 sequence substantially complementary to a segment of HAV  
nucleic acid; and

a second segment comprising a nucleotide  
sequence substantially complementary to an  
oligonucleotide bound to a solid phase, wherein said  
15 first segment is selected from the group consisting of

CGCAACGGCCAGAGCCTAGGGCAAGGGGAGAGC (SEQ ID NO:28),  
CTCCATGCTAATCATGGAGTTGACCCCGCCGGG (SEQ ID NO:29),  
AMACATCTGYGTCCCAATTTAGACTCCTACAG (SEQ ID NO:30),  
20 GARAGCCAAGTTWACACTGCAAGGTGACGTYCC (SEQ ID NO:31),  
GCCTACCCCTTGTGGAAGATCAAAGAGRTTCAT (SEQ ID NO:32),  
ARGGTGTRGGRTTATCTGAACTTGAATYTCAA (SEQ ID NO:33),  
GAACCATRGACARATYARYCCYCTGYTGRA (SEQ ID NO:34),  
AKGATGCTATHGAACCATARCTYTGATCACYAG (SEQ ID NO:35),  
25 TGCAATTTAACARACCATGAGGATAAACAGTCA (SEQ ID NO:36), and  
ATGGAACCTTTATTCTAACYACATTGTTTRATRT (SEQ ID NO:37).

4. The synthetic oligonucleotide of claim 3,  
wherein said second segment comprises

30

CTTCTTTGGAGAAAGTGGTG (SEQ ID NO:39).

35

-56-

5. A set of synthetic oligonucleotides useful as amplifier probes in a sandwich hybridization assay for HAV comprising two oligonucleotides,

wherein each oligonucleotide comprises:

5 a first segment comprising a nucleotide sequence substantially complementary to a segment of HAV nucleic acid; and

a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide acid multimer,

10 wherein said HAV nucleic acid segment is selected from the group consisting of

ATAGAAGTATTAGCCTAAGAGGTTTCACCCGTA (SEQ ID NO:6),  
15 CCGCCGCTGTTRCCCTATCCAARGCATCTCTTC (SEQ ID NO:7),  
TGAATGGTTTTTGTCTTAACAACTCACCAATAT (SEQ ID NO:8),  
GCATCCACTGGATGAGAGYCAGTCCTCCGGCGT (SEQ ID NO:9),  
CTARAGACAGCCCTGACARTCAATCCACTCAAT (SEQ ID NO:10),  
TTGCCCTAAGCACAGAGAGGTCTGRRATTAARC (SEQ ID NO:11),  
20 TCTCACAGRATCCCATTAAAGGCCAAATGRTGT (SEQ ID NO:12),  
AAGAACAGTCCAGCTGTCAATGGAGGGAYCCCC (SEQ ID NO:13),  
GTACCTCAGAGGCAAACACCACATAAGGCCCCA (SEQ ID NO:14),  
TTTAAGAATGAGGAAAAACCTAAATGCCCTGA (SEQ ID NO:15),  
GGAAAATWCCTTGTYTRGACATRTTCATTATTR (SEQ ID NO:16),  
25 ACAGGATGTGGTCAAGRCCACTCCCRACAGTCT (SEQ ID NO:17),  
GAATCATTGCTCTTCCTCAATRTCTGCCAAAG (SEQ ID NO:18),  
AAGCWCCAGTCACTGCAGTCCTAWCAACKGAYT (SEQ ID NO:19),  
GAACTGAAGATTGRTCCACAGAAGTRAARTAAG (SEQ ID NO:20),  
GTTCAAYYTGRTGTRAKCCAACCTCAGCWGTAT (SEQ ID NO:21),  
30 TWGAACYRGGTTTATCAACAGAGGTTYTCAARG (SEQ ID NO:22),  
GAATCARGAAAAAYTTYTCYCCCTGAGTYYTCT (SEQ ID NO:23),  
ADAGAGCATGTGTAGTRAGCCAATCWGCAGAAT (SEQ ID NO:24),  
RTTTCACCACRTCCAATTTTGCAACTTCATGRA (SEQ ID NO:25),  
AMCCTTGRACRGCAAACCTGCTCATTRTAYARTA (SEQ ID NO:26), and  
35 TGCCAAATCTTGCATATGTRTGGTATCTCAACA (SEQ ID NO:27).

-57-

6. The synthetic oligonucleotide of claim 5,  
wherein said second segment comprises

AGGCATAGGACCCGTGTCTT (SEQ ID NO:38).

5

7. A set of synthetic oligonucleotides useful  
as capture probes in a sandwich hybridization assay for  
HAV comprising two oligonucleotides,

wherein each oligonucleotide comprises:

10 a first segment comprising a nucleotide  
sequence substantially complementary to a segment of HAV  
nucleic acid; and

a second segment comprising a nucleotide  
sequence substantially complementary to an  
15 oligonucleotide bound to a solid phase,

wherein said HAV nucleic acid segment is  
selected from the group consisting of

20 CGCAACGGCCAGAGCCTAGGGCAAGGGGAGAGC (SEQ ID NO:28),  
CTCCATGCTAATCATGGAGTTGACCCGCGGG (SEQ ID NO:29),  
AMACATCTGYGTCCCAATTTAGACTCCTACAG (SEQ ID NO:30),  
GARAGCCAAGTTWACACTGCAAGGTGACGTYCC (SEQ ID NO:31),  
GCCTACCCCTTGTGGAAGATCAAAGAGRTTCAT (SEQ ID NO:32),  
ARGGTGTRGGRTTATCTGAACTTGAATYTCAA (SEQ ID NO:33),  
25 GAACCATRGACACARATYARYCCYCCYTGYTGRA (SEQ ID NO:34),  
AKGATGCTATHGAACCATARCTYTGGTCACYAG (SEQ ID NO:35),  
TGCAATTTAACARACCATGAGGATAAACAGTCA (SEQ ID NO:36), and  
ATGGAACCTTTATTCTAACYACATTGTTRATRT (SEQ ID NO:37).

30 8. The synthetic oligonucleotide of claim 7,  
wherein said second segment comprises

CTTCTTTGGAGAAAGTGGTG (SEQ ID NO:39).

35

-58-

9. A solution sandwich hybridization assay for detecting the presence of HAV in a sample, comprising

- (a) contacting the sample under hybridizing conditions with an excess of (i) amplifier probes comprising the set of synthetic oligonucleotides of claim 5 and (ii) a capture probe oligonucleotide comprising a first segment comprising a nucleotide sequence that is substantially complementary to a segment of HAV RNA and a second segment that is substantially complementary to an oligonucleotide bound to a solid phase;
- (b) contacting the product of step (a) under hybridizing conditions with said oligonucleotide bound to the solid phase;
- (c) thereafter separating materials not bound to the solid phase;
- (d) contacting the bound product of step (c) under hybridization conditions with the nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to the second segment of the amplifier probe polynucleotide and a multiplicity of second oligonucleotide units that are substantially complementary to a labeled oligonucleotide;
- (e) removing unbound multimer;
- (f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;
- (g) removing unbound labeled oligonucleotide; and
- (h) detecting the presence of label in the solid phase complex product of step (g).

10. A solution sandwich hybridization assay for detecting the presence of HAV in a sample, comprising (a) contacting the sample under hybridizing conditions with an excess of (i) an amplifier probe oligonucleotide comprising a first segment comprising a nucleotide sequence substantially complementary to a segment of HAV RNA and a

-59-

second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a set of capture probes comprising the set of synthetic oligonucleotides of claim

5 7;

(b) contacting the product of step (a) under hybridizing conditions with said oligonucleotide bound to the solid phase;

10 (c) thereafter separating materials not bound to the solid phase;

(d) contacting the bound product of step (c) under hybridization conditions with the nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to  
15 the second segment of the amplifier probe polynucleotide and a multiplicity of second oligonucleotide units that are substantially complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

20 (f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide;  
and

25 (h) detecting the presence of label in the solid phase complex product of step (g).

11. A kit for the detection of HAV in a sample comprising in combination

(i) a set of amplifier probe oligonucleotides  
30 wherein the amplifier probe oligonucleotide comprises a first segment comprising a nucleotide sequence substantially complementary to a segment of HAV nucleic acid and a second segment comprising a nucleotide sequence substantially complementary to an oligonucleotide unit of a  
35 nucleic acid multimer;

(ii) a set of capture probe oligonucleotides wherein the capture probe oligonucleotide comprises a first

-60-

segment comprising a nucleotide sequence that is substantially complementary to a segment of HAV nucleic acid and a second segment that is substantially complementary to an oligonucleotide bound to a solid phase;

- 5 (iii) a nucleic acid multimer, said multimer comprising at least one oligonucleotide unit that is substantially complementary to the second segment of the amplifier probe polynucleotide and at least one second oligonucleotide unit that is substantially complementary to  
10 a labeled oligonucleotide; and  
(iv) a labeled oligonucleotide.

12. The kit of claim 11, further comprising instructions for the use thereof.

15

13. The kit of claim 11, wherein said set of amplifier probe oligonucleotides comprises the set of synthetic oligonucleotides of claim 5.

20

14. The kit of claim 11, wherein said set of capture probe oligonucleotides comprises the set of synthetic oligonucleotides of claim 7.

25

30

35

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/11348

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(5) :C12Q 1/68 US CL :436/6 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 436/5,6,91,235.1; 436/501; 536/22.1,23.1,24.2,24.31,24.32; 935/78 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, MEDLINE, CAS, WPI, BIOTECH ABS, BIOSIS, GENE BANK		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,828,979 (Klevan et al.) 09 May 1989, see entire document but especially column 5, lines 17-37.	1-14
Y	US, A, 4,868,105 (Urdea et al.) 19 September 1989, see entire document.	1-14
Y	Journal of Virology, Volume 61, Number 1, issued January 1987, Cohen et al., "Complete Nucleotide Sequence of Wild-Type Hepatitis A Virus: Comparison with Different Strains of Hepatitis A Virus and Other Picornaviruses", pages 50-59, see especially the abstract and Figure 1 on pages 52-55.	1-14
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family	
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 31 March 1993	Date of mailing of the international search report 09 APR 1993	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer ARDIN MARSCHEL <i>Ardin Marschel for</i>	
Facsimile No. NOT APPLICABLE	Telephone No. (703) 308-0196	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/11348

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,894,228 (Purcell et al.) 16 January 1990, see especially Figures 1A-II.	1-14
Y	US, A, 4,894,325 (Englehardt et al.) 16 January 1990, see especially column 8, line 43, through column 11, line 4.	1-14
Y	Proceedings of the National Academy of Sciences, Volume 80, issued October 1983, Ticehurst et al., "Molecular cloning and characterization of hepatitis A virus cDNA", pages 5885-5889, see especially the abstract and the sequence on page 5889 in Figure 5.	1-14
Y	Journal of Virology, Volume 63, Number 11, issued November 1989, Brown et al., "Characterization of a Simian Hepatitis A Virus (HAV): Antigenic and Genetic Comparison with Human HAV", pages 4932-4937, see especially the abstract and Figure 4 on page 4935.	1-14
Y	Journal of Virology, Volume 54, Number 2, issued May 1985, Linemeyer et al., "Molecular Cloning and Partial Sequencing of Hepatitis A Viral cDNA", pages 247-255, see especially the abstract and the sequence on page 252.	1-14
A	Applied and Environmental Microbiology, Volume 52, Number 4, issued October 1986, Jiang et al., "Detection of Hepatitis A Virus in Seeded Estuarine Samples by Hybridization with cDNA Probes", pages 711-717, see especially the abstract.	1-14
A	Journal of Virology, Volume 61, Number 3, issued March 1987, Lemon et al., "Genomic Heterogeneity among Human and Nonhuman Strains of Hepatitis A Virus", pages 735-742, see especially the abstract.	1-14
A	Journal of Clinical Microbiology, Volume 27, Number 5, issued May 1989, Jiang et al., "In Situ Hybridization for Quantitative Assay of Infectious Hepatitis A Virus", pages 874-879, see especially the abstract.	1-14
A	Journal of Clinical Microbiology, Volume 22, Number 6, issued December 1985, Jansen et al., "Combined Immunoaffinity cDNA-RNA Hybridization Assay for Detection of Hepatitis A Virus in Clinical Specimens", pages 984-989, see especially the abstract.	1-14
A	Applied and Environmental Microbiology, Volume 53, Number 10, issued October 1987, Jiang et al., "Detection of Hepatitis A Virus by Hybridization with Single-Stranded RNA Probes", pages 2487-2495, see especially the abstract.	1-14



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/11348

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Journal of General Virology, Volume 67, issued 1986, Ross et al., "Molecular Cloning of cDNA from Hepatitis A Virus Strain HM-175 after Multiple Passages <u>in-vivo</u> and <u>in-vitro</u> ", pages 1741-1744, see especially the summary on page 1741.	1-14
A	Journal of Virological Methods, Volume 31, issued January 1991, Shieh et al., "Detection of hepatitis A virus and other enteroviruses in water by ssRNA probes", pages 119-136, see especially the summary on page 119-120.	1-14
A	Journal of Virological Methods, Volume 3, issued 1981, Von Der Helm et al., "Cloning of Hepatitis A Virus Genome", pages 37-43, see especially the abstract.	1-14

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**